Daiichi to market Nycomed imaging agent in Japan:
This article was originally published in Clinica
Executive Summary
Daiichi is to market Nycomed Amersham's ultrasound imaging agent, NC-100100, in Japan. The product will be used in cardiology and radiology applications, including liver imaging. It will be submitted for approval in the US and Europe at the end of this year. Development in Japan is at the preclinical stage. Daiichi already markets selected Nycomed imaging agents in Japan, including the non-ionic X-ray contrast medium, Omnipaque (iohexol). Nycomed Amersham estimates the potential worldwide market for ultrasound imaging to be around $1.6 billion.